Immunis, Inc., a clinical-stage biotech company, secured $25 million in Series A-1 funding to advance two Phase 2 clinical trials for its multi-active biologic targeting age and disease-related immune dysregulation. Existing investors, including Remiges Ventures, Continuum Health Ventures, and BOLD Capital Partners, participated in the round, alongside new investors like LifeSpan Vision Ventures and JLS Fund. The funding will support the clinical development of IMM01-STEM, a stem cell-derived therapy aimed at mitigating age-related muscle loss and improving metabolic function.
This development is crucial because it addresses the significant unmet medical need of age-related decline in muscle mass and metabolic function, which contributes to decreased quality of life and increased healthcare costs. Successful clinical trials could establish IMM01-STEM as a valuable therapeutic option for elderly individuals struggling with sarcopenia and metabolic dysfunction, offering the potential to improve physical function, reduce pain, and enhance overall well-being.
The Phase 2 trials follow a positive Phase 1/2a study that demonstrated the safety and tolerability of IMM01-STEM in elderly patients with age-related muscle atrophy. Initial results also suggested improvements in quality of life, including physical function and pain reduction, as well as increased gait speed. Preclinical studies in mouse models further support the therapy’s potential, showing reversal of muscle atrophy, improved muscle function, enhanced metabolism, and decreased body and liver fat. The new funding will allow Immunis to conduct larger, more rigorous studies to confirm these findings in a human population.
This successful funding round positions Immunis to solidify its leadership in the development of stem cell-derived multi-active biologics. Positive Phase 2 results could pave the way for larger trials and eventual regulatory approval, ultimately bringing a novel therapeutic option to patients and potentially transforming the management of age-related decline.
Source link: http://www.businesswire.com/news/home/20250111808660/en/Immunis-Closes-25-Million-Series-A-1-Financing-Round
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
